From podcasts and Q&As to articles and contributed bylines, BriaCell CEO Dr. William Williams has recently shared his perspective on BriaCell’s progress and novel approach to cancer immunotherapy.
We invite you to read and listen to these recent interviews and features to learn more about BriaCell, our approach, and the evolving cancer treatment landscape: briacell.com/media-coverage/ $BCTX $BCTXL
Dr. William V. Williams, President & CEO of BriaCell, joins the Biotech Insiders podcast to discuss the Company’s latest developments, vision for the future and opportunities ahead.
Listen to the full episode: bit.ly/3VrB3Tv $BCTX $BCTXL
What’s next for BriaCell’s multipronged approach to cancer #immunotherapy?
Dr. William V. Williams, President & CEO, discusses BriaCell’s innovative platform, advancing pipeline and opportunities ahead in a new Q&A with @digitaljournal.
Read more: bit.ly/4rtPAdy $BCTX $BCTXL
BriaCell is developing Bria-PROS+™ for prostate cancer.
This #ProstateCancerAwarenessMonth, please join us in the fight against prostate cancer. bit.ly/4fNH4An
#ProstateCancer #Immunotherapy #GetScreened
This September, BriaCell is proud to join the fight against prostate cancer.
We are currently developing Bria-PROS+™, a novel cell-based immunotherapy candidate for prostate cancer. bit.ly/4fNH4An
#ProstateCancerAwarenessMonth #ProstateCancer #Immunotherapy #GetScreened
“We are very encouraged by the DSMB’s seventh consecutive positive recommendation to continue BriaCell’s pivotal Phase 3 Bria-ABC study,” stated Dr. William V. Williams, President and Chief Executive Officer of BriaCell. For more information, visit: bit.ly/4h4o6WZ $BCTX $BCTXL
BriaCell announced that the independent Data Safety Monitoring Board (DSMB) has issued its seventh consecutive positive recommendation following review of clinical data from BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with #metastaticbreastcancer. Find details: bit.ly/4h4o6WZ $BCTX $BCTXL
Help Shape the Future of Cancer Treatment!
BriaCell Therapeutics is building its team. If you’re looking for an opportunity to contribute to innovative oncology programs, we’d love to hear from you.
Take the next step in your career and discover opportunities at BriaCell: bit.ly/478ecPX
This #ProstateCancerAwarenessMonth, BriaCell is advancing Bria-PROS+™ for prostate cancer.
Please join BriaCell in the fight against prostate cancer. bit.ly/4fNH4An
#ProstateCancer #Immunotherapy #GetScreened
Phaedon Zavras, MD, MSK Breast Medical Oncologist and Assistant Attending Physician and Principal Investigator for the MSK study site, discusses @MSKCancerCenter’s participation in BriaCell’s pivotal Phase 3 study of Bria-IMT™ in #metastaticbreastcancer. bit.ly/4yo8VyT $BCTX $BCTXL
“We are pleased to welcome @MSKCancerCenter as a clinical site in BriaCell’s Phase 3 study,” stated Dr. William V. Williams, BriaCell’s President & CEO. Learn more about BriaCell's pivotal Phase 3 study in #metastaticbreastcancer: bit.ly/4yo8VyT $BCTX $BCTXL
BriaCell announced that @MSKCancerCenter (MSK) has joined BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor in #metastaticbreastcancer (ClinicalTrials.gov identifier: NCT06072612). Find details: feeds.issuerdirect.com/news-… $BCTX $BCTXL
We’re Hiring at BriaCell!
Join a team advancing innovative cancer immunotherapies and helping bring new treatment approaches to patients.
Current Openings:
• Scientist/Senior Scientist – QC – Philadelphia, USA
• Scientist – Translational Biomarkers & Immunomonitoring
• Clinical Research Associate Intern
If you’re passionate about oncology, biotechnology and advancing the future of cancer treatment, we’d love to hear from you.
Explore the opportunities and apply: briacell.com/careers/
In a guest column for Drug Discovery Online, BriaCell CEO William V. Williams, MD, FACP, discusses the path to personalized scalable solid tumor immunotherapies. Read the full article: bit.ly/4gLkU2p $BCTX $BCTXL
#DrugDiscoveryOnline #Merck #Moderna
BriaCell is expanding its personalized, cell-based #immunotherapy approach across multiple cancer indications.
In a new @Inside_PM article, Bria-MEL+, BriaCell's personalized whole cell #melanoma immunotherapy vaccine candidate is highlighted alongside BriaCell’s Phase 3 trial of Bria-IMT™ in #metastaticbreastcancer and Bria-PROS+ in #prostatecancer.
Read more: bit.ly/46u9Guc $BCTX $BCTXL
“The future of cellular oncology lies in off-the-shelf, targeted platforms.”
In a new @pharmaphorum article, BriaCell President & CEO William V. Williams examines the innovation gap in #oncology and the need for scalable approaches to #cellular #immunotherapy.
The article explores how off-the-shelf cell platforms could reduce production costs, lower health system burdens and eliminate critical treatment delays, while next-generation whole-cell and platform approaches may help address the complex, immunosuppressive environments of solid tumours.
Dr. Williams also discusses adaptive clinical trial protocols and the importance of aligning early clinical strategies with the realities of late-stage development and commercialisation.
Read the full article: bit.ly/4ygcKWD $BCTX $BCTXL #PharmaPhorum
Explore Your Next Opportunity at BriaCell.
At BriaCell Therapeutics, our team is working to advance innovative cancer treatments and make a meaningful impact in oncology.
Current openings include:
• Scientist/Senior Scientist – QC – Philadelphia, USA
• Scientist (Translational Biomarkers & Immunomonitoring)
• Clinical Research Associate Intern
Interested in being part of the team? View open positions and learn more: briacell.com/careers/
September is Prostate Cancer Awareness Month, a timely reminder of the urgent need for advanced treatment options.
With FDA clearance of our IND application for Bria-PROS+™, our team is preparing to initiate a Phase 1/2a clinical trial. Bria-PROS+™ is our next-generation, off-the-shelf, personalized cell-based immunotherapy designed to activate the body's immune system against advanced prostate cancer.
As September approaches, our commitment to delivering innovative immuno-oncology solutions to patients who need them most is stronger than ever.
Learn more here: bit.ly/4fNH4An
#ProstateCancerAwareness #ProstateCancer #GetScreened #ProstateAwarenessMonth
ICYMI: BriaCell is advancing Bria-MEL+™, its personalized whole-cell melanoma immunotherapy vaccine candidate, toward clinical development following a key genetic engineering milestone.
Bria-MEL+ is designed to be personalized yet “off-the-shelf”: a simple patient saliva test will determine which of several premanufactured treatment cell lines will be selected for personalized treatment, avoiding the need to manufacture a unique product for each individual patient. For more: bit.ly/4xjGX7p $BCTX $BCTXL
As personalized cancer vaccines gain momentum, BriaCell is advancing a distinct approach with Bria-MEL+.
As highlighted by @Inside_PM, Bria-MEL+ is designed as a personalized, off-the-shelf cellular #immunotherapy for #melanoma—using a simple saliva test to identify the premanufactured cell line selected through patient HLA matching.
Read the full article: bit.ly/46u9Guc $BCTX $BCTXL #InsidePrecisionMedicine